11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring
    13.
    发明授权
    11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring 失效
    11beta取代的19-nor-17-α-前 - 1,3,5(10) - 三烯-17β-酯与21,16α-内酯环

    公开(公告)号:US06956031B2

    公开(公告)日:2005-10-18

    申请号:US10397855

    申请日:2003-03-27

    CPC分类号: C07J17/00

    摘要: This invention relates to new 19-nor-17α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring with a long-chain substituent in 11β-position of general formula II in which R11 is a long-chain alkyl radical that has a nitrogen atom that can be substituted in terminal position with a perfluoroalkyl group. The compounds act in a tissue-selective manner as pure antiestrogens and are suitable for the production of pharmaceutical agents because of these properties.

    摘要翻译: 本发明涉及具有21,16α-内酯环的新的19-nor-17α-前 - 1,3,5(10) - 三烯-17β-环,其通式II在11b位具有长链取代基 其中R 11是具有可以在末端被全氟烷基取代的氮原子的长链烷基。 化合物以组织选择性的方式作为纯抗雌激素起作用,并且由于这些性质而适用于制药。

    COMBINATION OF PROGESTERONE-RECEPTOR ANTAGONIST TOGETHER WITH NONE-STEROIDAL ANTIESTROGEN FOR USE IN BRCA MEDIATED DISEASES
    20.
    发明申请
    COMBINATION OF PROGESTERONE-RECEPTOR ANTAGONIST TOGETHER WITH NONE-STEROIDAL ANTIESTROGEN FOR USE IN BRCA MEDIATED DISEASES 审中-公开
    孕激素受体拮抗剂与无症状性静脉注射用于BRCA介导的疾病的组合

    公开(公告)号:US20080268041A1

    公开(公告)日:2008-10-30

    申请号:US12105357

    申请日:2008-04-18

    IPC分类号: A61K9/48 A61K31/575 A61P35/00

    摘要: The present invention relates to the combination of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one none-steroidal antiestrogen and to the use of said combination for the prophylaxis and treatment of BRCA1- or BRCA2-mediated diseases. None-steroidal antiestrogens which can be combined together with the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one are for example is tamoxifen, raloxifene, droloxifen, toremifen, lasofoxifen, arzoxifen, GW5638, EM-800, idoxifen and basedoxifene.

    摘要翻译: 本发明涉及孕酮受体拮抗剂11beta-(4-乙酰基苯基)-17β-羟基-17α-(1,1,2,2,2-五氟乙基) - 雌-4,9-二烯-3 一种或其药学上可接受的衍生物或类似物,以及至少一种非甾体抗雌激素,以及所述组合用于预防和治疗BRCA1或BRCA2介导的疾病的用途。 无甾体抗雌激素可与孕酮受体拮抗剂11beta-(4-乙酰基苯基)-17β-羟基-17α-(1,1,2,2,2-五氟乙基) - 雌-4,9-二烯 例如,他莫昔芬,雷洛昔芬,屈昔洛芬,托瑞米芬,拉索福昔芬,阿唑西芬,GW5638,EM-800,艾多昔芬和依诺昔芬。